Ars Pharmaceuticals, INC Form 4 insider transactions

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported the sale of common stock through various trusts, as disclosed in a recent SEC Form 4 filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed sales of common stock on August 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed sales of common stock on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed sales of common stock on July 9, 2024, according to a recent SEC filing.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on July 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management, along with related entities and individuals, reports acquiring stock options in ARS Pharmaceuticals.

Director Rajeev Dadoo reports acquisition of stock options in ARS Pharmaceuticals.

Director Pratik Shah acquired 40,000 stock options in ARS Pharmaceuticals, Inc. on June 20, 2024.

Director Laura Shawver acquired 40,000 stock options in ARS Pharmaceuticals, Inc. on June 20, 2024.

Director Phillip M Schneider reports acquisition of 40,000 stock options in ARS Pharmaceuticals, Inc.

Director Saqib Islam of ARS Pharmaceuticals acquired 40,000 stock options on June 20, 2024, exercisable at $7.73, vesting on June 20, 2025, or the date of the 2025 annual meeting.

Michael Kelly, a director of ARS Pharmaceuticals, acquired 40,000 stock options on June 20, 2024, according to a recent SEC filing.

Peter A. Thompson, a director of ARS Pharmaceuticals, acquired stock options for 40,000 shares of common stock on June 20, 2024.

Brent L Saunders, a director at ARS Pharmaceuticals, acquired 40,000 stock options on June 20, 2024, exercisable at $7.73, vesting on June 20, 2025, or the date of the 2025 annual meeting.

Director Pratik Shah reports gifting shares of ARS Pharmaceuticals stock, both directly and indirectly through his spouse, in transactions dated June 13, 2024.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between June 11 and June 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reported the sale of common stock shares across multiple transactions, as detailed in a recent SEC Form 4 filing.

Pratik Shah, a director and 10% owner of ARS Pharmaceuticals, reported a gift transaction involving common stock on June 7, 2024.

Pratik Shah, a director and 10% owner of ARS Pharmaceuticals, amended a previous Form 4 filing to clarify details regarding the transfer of shares from The Pratik Shah Living Trust to two irrevocable trusts for the benefit of his sons.

Pratik Shah, a director and 10% owner of ARS Pharmaceuticals, executed several transactions involving the transfer of common stock to trusts and as a gift to his spouse.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed multiple sales of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, exercised stock options at prices of $0.84 and $1.44, resulting in adjustments to her direct and indirect beneficial ownership of the company's common stock.

Richard Lowenthal, CEO of ARS Pharmaceuticals, reports the acquisition and disposal of common stock and stock options, both directly and indirectly through trusts and spousal holdings.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, reports exercising stock options, increasing her indirect beneficial ownership through spousal and trust holdings.

Richard E. Lowenthal, CEO of ARS Pharmaceuticals, exercised stock options at prices of $0.84 and $1.44, while maintaining beneficial ownership of over 4 million shares.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on April 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.